Skilarence (dimethyl fumarate) vs Ilumya (tildrakizumab)
Skilarence (dimethyl fumarate) vs Ilumya (tildrakizumab)
Skilarence (dimethyl fumarate) is an oral medication used for the treatment of moderate to severe plaque psoriasis, working by modulating the immune system to reduce inflammation. Ilumya (tildrakizumab), on the other hand, is a biologic injectable drug that targets a specific protein involved in the inflammatory process of psoriasis, offering a more targeted approach. When deciding between the two, a patient should consider factors such as the severity of their condition, route of administration preference, potential side effects, and any pre-existing health conditions that may influence drug efficacy or safety.
Difference between Skilarence and Ilumya
Metric | Skilarence (dimethyl fumarate) | Ilumya (tildrakizumab) |
---|---|---|
Generic name | Dimethyl fumarate | Tildrakizumab |
Indications | Psoriasis | Plaque psoriasis |
Mechanism of action | Activates the Nrf2 antioxidant pathway | Interleukin-23 antagonist |
Brand names | Skilarence, Tecfidera | Ilumya |
Administrative route | Oral | Subcutaneous injection |
Side effects | Flushing, gastrointestinal issues, lymphopenia | Upper respiratory infections, injection site reactions, diarrhea |
Contraindications | Known hypersensitivity to dimethyl fumarate or any of the excipients | Known hypersensitivity to tildrakizumab or any of the excipients |
Drug class | Fumaric acid ester | Monoclonal antibody |
Manufacturer | Almirall, Biogen | Sun Pharma, Merck & Co. |
Efficacy
Skilarence (Dimethyl Fumarate) for Psoriasis
Skilarence, containing the active ingredient dimethyl fumarate, is an oral medication approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells leading to thick, red, scaly patches on the skin. The efficacy of Skilarence in the treatment of psoriasis has been demonstrated in several clinical trials. In these studies, Skilarence has been shown to significantly reduce the Psoriasis Area and Severity Index (PASI) score, which is a measure of the severity and extent of psoriasis, indicating an improvement in the condition of the skin.
The therapeutic effects of Skilarence are thought to be due to its anti-inflammatory and immunomodulatory properties. Patients treated with Skilarence have reported a reduction in the thickness, scaling, and redness of psoriatic plaques. Additionally, improvements in quality of life measures have also been observed, which is an important consideration in a chronic disease like psoriasis that can significantly impact daily functioning and well-being.
Ilumya (Tildrakizumab) for Psoriasis
Ilumya, with the active substance tildrakizumab, is a biologic medication administered via injection for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the inflammatory processes of psoriasis. Clinical trials have shown that Ilumya is effective in achieving clear or almost clear skin as measured by PASI 75 (75% reduction in PASI score) and PASI 90 responses in a significant proportion of patients.
The efficacy of Ilumya has been maintained in long-term studies, with sustained responses over time, which is crucial for the management of a chronic condition like psoriasis. The treatment has been well-tolerated, with a safety profile that supports its use in the long-term management of psoriasis. The ability of Ilumya to provide sustained symptom control with infrequent dosing (typically every 12 weeks after initial doses) is beneficial for patient adherence and quality of life.
Regulatory Agency Approvals
Skilarence
Ilumya
Access Skilarence or Ilumya today
If Skilarence or Ilumya are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us